PMC:7795856 / 18424-18638 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"306","span":{"begin":136,"end":139},"obj":"Gene"},{"id":"315","span":{"begin":173,"end":179},"obj":"Disease"}],"attributes":[{"id":"A306","pred":"tao:has_database_id","subj":"306","obj":"Gene:134864"},{"id":"A315","pred":"tao:has_database_id","subj":"315","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ife, which results in a strongly enhanced bioactivity as demonstrated for multiple PASylated biopharmaceuticals [37,54]. In the case of Tα1, superior effects in preclinical cancer models due to prolonged circulatio"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T16","span":{"begin":173,"end":179},"obj":"Phenotype"}],"attributes":[{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"ife, which results in a strongly enhanced bioactivity as demonstrated for multiple PASylated biopharmaceuticals [37,54]. In the case of Tα1, superior effects in preclinical cancer models due to prolonged circulatio"}